[Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals]

Dtsch Med Wochenschr. 2005 May 27;130(21):1318-22. doi: 10.1055/s-2005-868727.

[Article in German]

Authors

C F Grimm¹, H E Blum, M Geissler

Affiliation

¹ Abteilung Innere Medizin II, Medizinische Universitätsklinik Freiburg. [email protected]

PMID: 15902620
DOI: 10.1055/s-2005-868727

No abstract available

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / therapeutic use*
Benzamides
Dimerization
Enzyme Activation / genetics
Enzyme Activation / physiology
Growth Substances / genetics
Growth Substances / metabolism
Humans
Imatinib Mesylate
Neoplasms / blood supply
Neoplasms / drug therapy*
Neoplasms / genetics
Neovascularization, Pathologic
Piperazines / therapeutic use
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Protein-Tyrosine Kinases / genetics
Protein-Tyrosine Kinases / metabolism
Pyrimidines / therapeutic use
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
Receptor Protein-Tyrosine Kinases / chemistry
Receptor Protein-Tyrosine Kinases / metabolism*
Receptors, Growth Factor / genetics
Receptors, Growth Factor / metabolism
Receptors, Vascular Endothelial Growth Factor / physiology
Signal Transduction / genetics

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Benzamides
Growth Substances
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Receptors, Growth Factor
Imatinib Mesylate
Protein-Tyrosine Kinases
Receptor Protein-Tyrosine Kinases
Receptors, Vascular Endothelial Growth Factor